Table 1.

Cell cycle analysis upon GRPR/EGFR inhibitor treatment

Cell linePhaseControlPD176252ErlotinibPD176252 + erlotinib (P1,2)*
1483G0-G139.249.844.961.6 (P1 = 0.028; P2 = 0.028)
S29.827.429.221.5 (P1 = 0.028; P2 = 0.028)
G2-M26.418.722.014.2
  • * P value was determined for comparison of G0-G1, S or G2-M cell population in PD176252 (P1) or (P2) with that in the combined treatment by Wilcoxon test from four independent (1483) experiments, and multiple comparisons within the same experiment were adjusted with the Bonferroni procedure.